---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-093304"
form_type: "8-K"
ticker: "AMLX"
cik: "0001658551"
company_name: "Amylyx Pharmaceuticals, Inc."
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T10:58:52.107065+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Amylyx Q2 net loss $72.7M; revenue negative after RELYVRIO withdrawal; avexitide acquisition

## Summary
- Q2 net loss $72.7M ($1.07/share) vs net income $22.1M ($0.31) a year ago; revenue negative $(1.0)M after RELYVRIO/ALBRIOZA withdrawal.
- Cash $309.8M at June 30, down from $373.3M at March 31; runway into 2026.
- Acquired avexitide (GLP-1 antagonist) with FDA Breakthrough Therapy; PBH Phase 3 plan Q1 2025.
- Restructuring $22.9M largely severance; headcount reduced after PHOENIX failure and product discontinuation.
- R&D down to $23.3M, SG&A to $21.6M; cost cuts and pipeline shift from RELYVRIO.

## SEC filing metadata
- accession: 0000950170-24-093304
- form_type: 8-K
- ticker: AMLX
- cik: 0001658551
- company_name: Amylyx Pharmaceuticals, Inc.
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1658551/000095017024093304/0000950170-24-093304-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1658551/000095017024093304/amlx-20240808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-093304
- JSON: https://secwatch.observer/filing/0000950170-24-093304.json
- Plain text: https://secwatch.observer/filing/0000950170-24-093304.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.